Activation specific CD11b inhibition mitigates immune checkpoint inhibitor associated cardiac and intestinal toxicity while preserving anti tumor effects

Clicks: 1
ID: 323299
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #159 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Immune checkpoint inhibitors (ICI) can induce myocarditis and colitis through excessive immune activation and myeloid-dependent tissue infiltration. Current treatment strategies rely on broad immunosuppression and may compromise anti-tumor immunity. We hypothesized that selective inhibition of activated CD11b (Mac-1) would limit pathogenic immune cell trafficking while preserving systemic T-cell responses and anti-tumor efficacy. Methods ICI toxicity was induced in wild-type mice using anti-PD-1 therapy. Mice were treated with Neutrophil Inhibitory Factor (NIF), an activation-specific CD11b inhibitor, or vehicle control. Cardiac injury was assessed by serum troponin and echocardiographic left ventricular ejection fraction (LVEF). Cardiac immune infiltrates were quantified by flow cytometry. Systemic cytokine profiles were assessed in serum using LEGENDplex bead-based multiplex assays. Colonic injury was evaluated by histological damage scoring on hematoxylin and eosin (H&E)-stained sections. CD11b-dependent adhesion was tested in vitro using ICAM-1-coated plates. To assess anti-tumor efficacy, a B16.F10 melanoma model was employed, and tumor progression was compared between anti-PD-1–treated mice with or without concomitant NIF administration. Results NIF treatment significantly reduced serum troponin levels and preserved LVEF compared with vehicle controls. Flow cytometric analysis of cardiac tissue demonstrated a marked and highly significant reduction of Ly6C^high monocytes, indicating effective blockade of activated myeloid cell infiltration, while absolute CD8⁺ T-cell numbers were not reduced. H&E analysis of colonic tissue revealed significantly less histological damage in NIF-treated mice compared with controls. LEGENDplex analysis demonstrated altered systemic cytokine profiles consistent with reduced tissue injury. In vitro, NIF dose-dependently inhibited CD11b–ICAM-1–mediated adhesion. Importantly, in the B16.F10 melanoma model, concomitant NIF treatment did not impair the anti-tumor efficacy of anti-PD-1 therapy, as tumor progression was comparable to anti-PD-1 treatment alone. Conclusions Activation-specific CD11b inhibition with NIF selectively blocks pathogenic Ly6C^high monocyte infiltration during ICI therapy, preserving cardiac function and reducing colonic tissue injury while sparing CD8⁺ T-cell abundance. Importantly, this protective effect does not compromise anti-tumor efficacy. Targeted CD11b inhibition therefore represents a precision strategy to mitigate ICI-associated toxicity without broad immunosuppression
Reference Key
openalex_W7172322516 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors I Bojti, A Ziegler, S Bojtne Kovacs, L Braun, N Jung, T Marchini, X Li, D Westermann, D Wolf
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.233
URL
https://doi.org/10.1093/eurheartjsupp/suag097.233
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.